Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Rachael A Safyan"'
Autor:
David B. Zhen, Rachael A. Safyan, Eric Q. Konick, Ryan Nguyen, Colin C. Prichard, E. Gabriela Chiorean
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 16 (2023)
Pancreatic ductal adenocarcinoma (PDA) is highly aggressive and has few treatment options. To personalize therapy, it is critical to delineate molecular subtypes and understand inter- and intra-tumoral heterogeneity. Germline testing for hereditary g
Externí odkaz:
https://doaj.org/article/fb652e64f16d4f0a91f3368c72bba34c
Autor:
Ravi P, Kiran, Gursimran S, Kochhar, Revital, Kariv, Douglas K, Rex, Akira, Sugita, David T, Rubin, Udayakumar, Navaneethan, Tracy L, Hull, Huaibin Mabel, Ko, Xiuli, Liu, Lisa A, Kachnic, Scott, Strong, Marietta, Iacucci, Willem, Bemelman, Philip, Fleshner, Rachael A, Safyan, Paulo G, Kotze, André, D'Hoore, Omar, Faiz, Simon, Lo, Jean H, Ashburn, Antonino, Spinelli, Charles N, Bernstein, Sunanda V, Kane, Raymond K, Cross, Jason, Schairer, James T, McCormick, Francis A, Farraye, Shannon, Chang, Ellen J, Scherl, David A, Schwartz, David H, Bruining, Jessica, Philpott, Stuart, Bentley-Hibbert, Dino, Tarabar, Sandra, El-Hachem, William J, Sandborn, Mark S, Silverberg, Darrell S, Pardi, James M, Church, Bo, Shen
Publikováno v:
The Lancet Gastroenterology & Hepatology. 7:871-893
Surveillance pouchoscopy is recommended for patients with restorative proctocolectomy with ileal pouch-anal anastomosis in ulcerative colitis or familial adenomatous polyposis, with the surveillance interval depending on the risk of neoplasia. Neopla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3ba492f9e025decc6dc6cc0fae4771a
https://doi.org/10.1016/s2468-1253(22)00039-5
https://doi.org/10.1016/s2468-1253(22)00039-5
Publikováno v:
Cancer Management and Research. 12:2731-2742
Pancreatic ductal adenocarcinoma (PDAC) remains a challenging disease to treat. Despite advances in surgical techniques, radiation, and medical therapies, the 5-year survival rate remains below 9%. Over the past decade, the genomic landscape of PDAC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::caaa9e91c9b2550287a81b0f764228db
https://doi.org/10.2147/cmar.s211151
https://doi.org/10.2147/cmar.s211151
Autor:
Meredith LaRose, Celine Yeh, Mengxi Zhou, Keith Magnus Sigel, Gayle S. Jameson, Ruth Aroon White, Rachael A Safyan, Yvonne M. Saenger, Elizabeth Hecht, John A. Chabot, Stephen M. Schreibman, Antonio Tito Fojo, Gulam Abbas Manji, Daniel D. Von Hoff, Susan Elaine Bates
Publikováno v:
Journal of Clinical Oncology. 41:726-726
726 Background: The development of new treatments in oncology is a long, costly, and, too often, unsuccessful process. Methods for screening agents earlier in development and strategies for conducting smaller randomized controlled trials are needed.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4f3d16a9845891d711e962aea1af87a6
https://doi.org/10.1200/jco.2023.41.4_suppl.726
https://doi.org/10.1200/jco.2023.41.4_suppl.726
Autor:
E. Gabriela Chiorean, Aude Chapuis, Andrew L. Coveler, Cecilia CS Yeung, Ted Gooley, David Bing Zhen, Gentry Teng King, Lindsay Marie Hannan, Stacey A. Cohen, Rachael A Safyan, Anthony Germani, Susan Ra, Jennifer Casserd, Thomas Schmitt, Philip D Greenberg
Publikováno v:
Journal of Clinical Oncology. 41:TPS779-TPS779
TPS779 Background: PDA has a low tumor mutational burden and an immunosuppressive microenvironment. Targeting overexpressed self-antigens with adoptive, genetically engineered, high affinity T cells may overcome immunosuppression (Stromnes I, Immunol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a42a731ca5e89decbfcf87adec003bf7
https://doi.org/10.1200/jco.2023.41.4_suppl.tps779
https://doi.org/10.1200/jco.2023.41.4_suppl.tps779
Autor:
J. Randolph Hecht, Ardaman Shergill, Mark Gregory Goldstein, Bruno Fang, May Thet Cho, Heinz-Josef Lenz, Lyudmyla Derby Berim, Paul Eliezer Oberstein, Rachael A Safyan, Vivek Sawhney, Heloisa P. Soares, David R. Spigel, Alexander I. Spira, Andrew R. Ferguson, Brian Chauder, Alexander Starodub
Publikováno v:
Journal of Clinical Oncology. 40:TPS3635-TPS3635
TPS3635 Background: Treatment options for most patients with metastatic colorectal cancer (mCRC) are largely limited to cytotoxic chemotherapy, with little advancement in the last decade. Encouragingly, a small subset of patients deficient in mismatc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0ff743a9d42e7eb5f7e1c0731bb39d2
https://doi.org/10.1200/jco.2022.40.16_suppl.tps3635
https://doi.org/10.1200/jco.2022.40.16_suppl.tps3635
Autor:
Rachael A Safyan, Gulam Abbas Manji, Shing Mirn Lee, Rebecca Silva, Susan Elaine Bates, Ruth Aroon White, Jacob K.R. Jamison, Adam Joel Bass, Gary K. Schwartz, Paul Eliezer Oberstein, Tamas Gonda
Publikováno v:
Journal of Clinical Oncology. 40:4158-4158
4158 Background: Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related death with a 5-year survival rate of 10%. Novel strategies for advanced PDAC are a critical need. A DNA hypomethylating agent (HMA) increased tumor-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86b18428e375e866ab0ee8529d8aaa4f
https://doi.org/10.1200/jco.2022.40.16_suppl.4158
https://doi.org/10.1200/jco.2022.40.16_suppl.4158
Autor:
Bo Shen, Gursimran Kochhar, Revital Kariv, Douglas K. Rex, Akira Sugita, David T. Rubin, Udayakumar Navaneethan, Tracy L. Hull, Huaibin M. Ko, Xiuli Liu, Scott A. Strong, Marietta Iacucci, Willem A. Bemelman, Phillip Fleshner, Rachael M. Safyan, Paulo G. Kotze, Andre D’Hoore, Omar Faiz, Simon K. Lo, Jean Ashburn, Antonino Spinelli, Charles N. Bernstein, Sunanda V. Kane, Raymond K. Cross, Jason Schairer, James T. McCormick, Francis A. Farraye, Shannon Chang, Ellen J. Scherl, David A. Schwartz, David H. Bruining, Jessica Philpott, Stuart Bentley-Hibbert, Dino Tarabar, Sandra El-Hachem, William J. Sandborn, Mark S. Silverberg, Darrell S. Pardi, James Church, Ravi P. Kiran
Publikováno v:
Gastroenterology. 162:S-785
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bba379640c579e434b4bf06b3cc599f6
https://doi.org/10.1016/s0016-5085(22)61858-4
https://doi.org/10.1016/s0016-5085(22)61858-4
Autor:
Michael S. May, Alissa Michel, Tristan Lee, Winston Wong, Jacob K.R. Jamison, David Manrique, Samuel M Pan, Jianhua Hu, Rachael A Safyan, Alexander Raufi, Michael Kluger, Susan Elaine Bates, John A. Chabot, Gulam Abbas Manji
Publikováno v:
Journal of Clinical Oncology. 40:608-608
608 Background: Recurrence rates after resection of pancreatic ductal adenocarcinoma (PDA) can be up to 80%. Prior data suggests that initial site of recurrence influences prognosis. This study aims to compare survival of patients (pts) with resected
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69429b22f4a12889d7492e1e00e8d891
https://doi.org/10.1200/jco.2022.40.4_suppl.608
https://doi.org/10.1200/jco.2022.40.4_suppl.608
Autor:
Winston Wong, Jacob K.R. Jamison, Michael S. May, Alissa Michel, Tristan Lee, David Manrique, Alexander Raufi, Samuel M Pan, Rachael A Safyan, David Paul Horowitz, Beth Schrope, Michael Kluger, Lisa A. Kachnic, Jianhua Hu, Susan Elaine Bates, John A. Chabot, Gulam Abbas Manji
Publikováno v:
Journal of Clinical Oncology. 40:565-565
565 Background: Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with a minority of patients (pts) eligible for curative resection. Currently, systemic treatment options for down-staging pts with borderline resectable or locally advance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2f2eaa13c9b78614803b572799bd5a38
https://doi.org/10.1200/jco.2022.40.4_suppl.565
https://doi.org/10.1200/jco.2022.40.4_suppl.565